

Statistical controversies in clinical research: basket trials master protocols: a review and examples

Annals of Oncology

28, 34-43

DOI: [10.1093/annonc/mdw413](https://doi.org/10.1093/annonc/mdw413)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e503-e506.	0.9	10
2	“Big data” approaches for novel anti-cancer drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 599-609.	2.5	9
3	A statistician's perspective on a long time to publish. <i>Lancet Haematology</i> , 2017, 4, e12.	2.2	0
4	(Very) Early technology assessment and translation of predictive biomarkers in breast cancer. <i>Cancer Treatment Reviews</i> , 2017, 52, 117-127.	3.4	13
5	The current status and problems confronted in delivering precision medicine in Japan and Europe. <i>Current Problems in Cancer</i> , 2017, 41, 166-175.	1.0	17
6	Precision oncology: neither a silver bullet nor a dream. <i>Pharmacogenomics</i> , 2017, 18, 1525-1539.	0.6	21
7	Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. <i>Clinical Cancer Research</i> , 2017, 23, 4950-4958.	3.2	46
8	Single-Subject Studies in Translational Nutrition Research. <i>Annual Review of Nutrition</i> , 2017, 37, 395-422.	4.3	64
9	Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview. <i>Journal of Clinical Epidemiology</i> , 2017, 90, 108-118.	2.4	26
11	Specifying the True- and False-Positive Rates in Basket Trials. <i>JCO Precision Oncology</i> , 2017, 1, 1-5.	1.5	7
12	Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 11.	1.3	3
13	A Multi-Source Adaptive Platform Design for Testing Sequential Combinatorial Therapeutic Strategies. <i>Biometrics</i> , 2018, 74, 1082-1094.	0.8	38
14	A Bayesian basket trial design using a calibrated Bayesian hierarchical model. <i>Clinical Trials</i> , 2018, 15, 149-158.	0.7	90
15	Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design. <i>Clinical Cancer Research</i> , 2018, 24, 994-1001.	3.2	10
16	Learning health systems, clinical equipoise and the ethics of response adaptive randomisation. <i>Journal of Medical Ethics</i> , 2018, 44, 409-415.	1.0	32
17	Drug development in the era of precision medicine. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 183-196.	21.5	294
18	Addressing small sample size bias in multiple biomarker trials: Inclusion of biomarker-negative patients and Firth correction. <i>Biometrical Journal</i> , 2018, 60, 275-287.	0.6	2
19	Reflections on the Present and Future State of Lung Cancer Research and Management. , 2018, , 243-249.		0

#	ARTICLE	IF	CITATIONS
22	Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway. <i>Cancer Biology and Medicine</i> , 2018, 15, 314.	1.4	6
23	Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. <i>Cancer</i> , 2018, 124, 4601-4609.	2.0	8
24	The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies. <i>European Journal of Cancer</i> , 2018, 103, 259-266.	1.3	13
25	Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. <i>Annals of Oncology</i> , 2018, 29, 2313-2327.	0.6	47
26	Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study. <i>Annals of Oncology</i> , 2018, 29, 2296-2301.	0.6	13
27	Master protocol trials in oncology: Review and new trial designs. <i>Contemporary Clinical Trials Communications</i> , 2018, 12, 1-8.	0.5	81
28	Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 75.	1.5	62
29	Bayesian basket trial design with exchangeability monitoring. <i>Statistics in Medicine</i> , 2018, 37, 3557-3572.	0.8	67
30	A pooled analysis of published, basket trials in cancer medicine. <i>European Journal of Cancer</i> , 2018, 101, 244-250.	1.3	19
31	Implementing precision cancer medicine in the genomic era. <i>Seminars in Cancer Biology</i> , 2019, 55, 16-27.	4.3	24
32	Design of experiments for a confirmatory trial of precision medicine. <i>Journal of Statistical Planning and Inference</i> , 2019, 199, 179-187.	0.4	3
33	Molecular Alterations and Heterogeneity in Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019, , 293-316.	0.4	4
34	Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy. <i>Hastings Center Report</i> , 2019, 49, 31-41.	0.7	23
35	Have clinical trials in HIV finally matured?. <i>Lancet HIV</i> , 2019, 6, e561-e563.	2.1	2
36	Reporting of master protocols towards a standardized approach: A systematic review. <i>Contemporary Clinical Trials Communications</i> , 2019, 15, 100406.	0.5	27
37	The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 634.	1.3	3
38	The future of clinical trials in urological oncology. <i>Nature Reviews Urology</i> , 2019, 16, 722-733.	1.9	5
40	A stroke recovery trial development framework: Consensus-based core recommendations from the Second Stroke Recovery and Rehabilitation Roundtable. <i>International Journal of Stroke</i> , 2019, 14, 792-802.	2.9	64

#	ARTICLE	IF	CITATIONS
41	A Stroke Recovery Trial Development Framework: Consensus-Based Core Recommendations from the Second Stroke Recovery and Rehabilitation Roundtable. <i>Neurorehabilitation and Neural Repair</i> , 2019, 33, 959-969.	1.4	24
42	Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on "preclinical and early-phase clinical pharmacology". <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1033-1036.	1.3	4
43	Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. <i>Trials</i> , 2019, 20, 572.	0.7	232
44	Challenges with Novel Clinical Trial Designs: Master Protocols. <i>Clinical Cancer Research</i> , 2019, 25, 2049-2057.	3.2	35
45	Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1907-1924.	1.1	15
46	A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1255-1262.	3.0	35
47	Testing monotherapy and combination therapy in one trial with biomarker consideration. <i>Contemporary Clinical Trials</i> , 2019, 82, 53-59.	0.8	1
48	Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. <i>Trials</i> , 2019, 20, 294.	0.7	37
49	Borrowing From Historical Control Data in Cancer Drug Development: A Cautionary Tale and Practical Guidelines. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 67-78.	0.6	27
50	A flexible parametric survival model for fitting time to event data in clinical trials. <i>Pharmaceutical Statistics</i> , 2019, 18, 555-567.	0.7	14
51	Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program. <i>Pharmaceutical Medicine</i> , 2019, 33, 89-98.	1.0	4
52	Emerging patient-specific treatment modalities in head and neck cancer "a systematic review. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 365-376.	1.9	3
53	On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. <i>Annals of Oncology</i> , 2019, 30, 506-509.	0.6	34
54	Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries. <i>ESMO Open</i> , 2019, 4, e000550.	2.0	33
55	Bayesian Basket Designs for Cancer Clinical Trials. <i>Japanese Journal of Biometrics</i> , 2019, 39, 103-122.	0.0	0
56	Overestimated treatment effects in randomised phase II trials: What's up doctor?. <i>European Journal of Cancer</i> , 2019, 123, 116-117.	1.3	2
57	Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	1.5	3
58	New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. <i>Cancer Treatment Reviews</i> , 2019, 73, 20-30.	3.4	116

#	ARTICLE	IF	CITATIONS
59	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019, 111, 118-128.	3.0	49
60	From the Double Helix to Oncogenomics and Precision Cancer Medicine. , 2019, , 3-16.		0
61	Clinical target sequencing for precision medicine of breast cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 131-140.	1.0	14
62	Innovation in oncology clinical trial design. <i>Cancer Treatment Reviews</i> , 2019, 74, 15-20.	3.4	41
63	Evidence-based data and rare cancers: The need for a new methodological approach in research and investigation. <i>European Journal of Surgical Oncology</i> , 2019, 45, 22-30.	0.5	16
64	Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. <i>Journal of the National Cancer Institute</i> , 2020, 112, 229-237.	3.0	15
65	Kidney disease trials for the 21st century: innovations in design and conduct. <i>Nature Reviews Nephrology</i> , 2020, 16, 173-185.	4.1	14
66	Molecular determinants of drug response in TNBC cell lines. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 337-347.	1.1	5
67	Licensing Nucleic Acid Amplification Tests for Extragenital Gonorrhoea and Chlamydia: Innovative Science and a Call to Arms. <i>Clinical Infectious Diseases</i> , 2020, 71, 2323-2325.	2.9	0
68	Paravertebral block with propofol anaesthesia does not improve survival compared with sevoflurane anaesthesia for breast cancer surgery: independent discussion of a randomised controlled trial. <i>British Journal of Anaesthesia</i> , 2020, 124, 19-24.	1.5	10
69	Regulatory Aspects of Genomic Medicine and Pharmacogenomics. , 2020, , 345-360.		1
70	Multiplicity issues for platform trials with a shared control arm. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1077-1090.	0.4	12
71	Grand challenges for medical physics in radiation oncology. <i>Radiotherapy and Oncology</i> , 2020, 153, 7-14.	0.3	33
72	Basket trials: From tumour gnostic to tumour agnostic drug development. <i>Cancer Treatment Reviews</i> , 2020, 90, 102082.	3.4	15
73	Alzheimer's disease drug development pipeline: 2020. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12050.	1.8	353
74	Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. <i>Cancer</i> , 2020, 126, 4735-4743.	2.0	11
75	A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations. <i>Pharmaceutical Statistics</i> , 2020, 19, 975-1000.	0.7	7
76	Flexible Bayesian subgroup analysis in early and confirmatory trials. <i>Contemporary Clinical Trials</i> , 2020, 98, 106149.	0.8	4

#	ARTICLE	IF	CITATIONS
77	Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system. <i>Spinal Cord</i> , 2020, 58, 1235-1248.	0.9	17
78	Clinical trial design: Past, present, and future in the context of big data and precision medicine. <i>Cancer</i> , 2020, 126, 4838-4846.	2.0	22
79	Effect size estimates from umbrella designs: Handling patients with a positive test result for multiple biomarkers using random or pragmatic subtrial allocation. <i>PLoS ONE</i> , 2020, 15, e0237441.	1.1	2
80	Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system. <i>Cancer Science</i> , 2020, 111, 3926-3937.	1.7	20
81	Impact of a Global Pandemic on Health Technology Assessment. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 339-343.	1.0	27
82	Pharmaceutical Innovations: The Grand Challenges Ahead. <i>Frontiers in Medical Technology</i> , 2020, 1, 3.	1.3	0
83	Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy. <i>Biostatistics</i> , 2022, 23, 120-135.	0.9	24
84	Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma. <i>Thoracic Cancer</i> , 2020, 11, 1979-1988.	0.8	3
85	Master protocols: New directions in drug discovery. <i>Contemporary Clinical Trials Communications</i> , 2020, 18, 100568.	0.5	21
86	Generating comparative evidence on new drugs and devices after approval. <i>Lancet, The</i> , 2020, 395, 998-1010.	6.3	52
87	Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints. <i>Statistical Methods in Medical Research</i> , 2020, 29, 2717-2732.	0.7	24
88	A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data. <i>Drug Safety</i> , 2020, 43, 623-633.	1.4	26
89	The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. <i>Clinical Therapeutics</i> , 2020, 42, 1330-1360.	1.1	74
90	Randomized Controlled Trials. <i>Chest</i> , 2020, 158, S79-S87.	0.4	48
91	An overview of precision oncology basket and umbrella trials for clinicians. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 125-137.	157.7	116
92	RoBoT: a robust Bayesian hypothesis testing method for basket trials. <i>Biostatistics</i> , 2021, 22, 897-912.	0.9	19
93	Improving the Time to Activation of New Clinical Trials at a National Cancer Institute-Designated Comprehensive Cancer Center. <i>JCO Oncology Practice</i> , 2020, 16, e324-e332.	1.4	7
94	Molecular profiling for precision cancer therapies. <i>Genome Medicine</i> , 2020, 12, 8.	3.6	447

#	ARTICLE	IF	CITATIONS
95	Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1059-1067.	2.3	61
96	Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to. <i>Annals of Hematology</i> , 2020, 99, 1161-1176.	0.8	9
97	Tumor-Agnostic Treatment for Cancer: When How is Better than Where. <i>Clinical Drug Investigation</i> , 2020, 40, 519-527.	1.1	32
98	Statistical design considerations for trials that study multiple indications. <i>Statistical Methods in Medical Research</i> , 2021, 30, 785-798.	0.7	9
99	Individual point-of-care trials: a new approach to incorporate patient's preferences into personalized pragmatic clinical trials. <i>Journal of Clinical Epidemiology</i> , 2021, 130, 152-155.	2.4	5
100	Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 248-258.	0.6	6
101	Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 133-146.	0.6	3
102	Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). <i>Statistics in Medicine</i> , 2021, 40, 2893-2921.	0.8	4
103	Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. <i>Trials</i> , 2021, 22, 203.	0.7	15
104	Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 433-468.	0.9	7
105	Novel Study Designs in Precision Medicine – Basket, Umbrella and Platform Trials. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2022, 17, 114-121.	0.4	6
106	Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. <i>Diagnostics</i> , 2021, 11, 469.	1.3	2
107	On the design and the analysis of stratified biomarker trials in the presence of measurement error. <i>Statistics in Medicine</i> , 2021, 40, 2783-2799.	0.8	0
108	Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs. <i>Statistics in Medicine</i> , 2021, 40, 2939-2956.	0.8	11
109	Implementing Historical Controls in Oncology Trials. <i>Oncologist</i> , 2021, 26, e859-e862.	1.9	12
110	Categories, components, and techniques in a modular construction of basket trials for application and further research. <i>Biometrical Journal</i> , 2021, 63, 1159-1184.	0.6	8
111	Randomised trials at the level of the individual. <i>The Lancet Global Health</i> , 2021, 9, e691-e700.	2.9	11
112	Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1145-1154.	0.8	31

#	ARTICLE	IF	CITATIONS
113	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
114	Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential. BMC Rheumatology, 2021, 5, 21.	0.6	8
115	Moving forward in clinical research with master protocols. Contemporary Clinical Trials, 2021, 106, 106438.	0.8	4
116	Progression Risk Score Estimation Based on Immunostaining Data in Oral Cancer Using Unsupervised Hierarchical Clustering Analysis: A Retrospective Study in Taiwan. Journal of Personalized Medicine, 2021, 11, 908.	1.1	0
117	Sample size estimation for cancer randomized trials in the presence of heterogeneous populations. Biometrics, 2022, 78, 1662-1673.	0.8	1
118	Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment. Lancet Oncology, The, 2021, 22, e430-e434.	5.1	24
119	Bridging across patient subgroups in phase I oncology trials that incorporate animal data. Statistical Methods in Medical Research, 2021, 30, 1057-1071.	0.7	2
120	Facing the urgency of therapies for progressive MS â€” a Progressive MS Alliance proposal. Nature Reviews Neurology, 2021, 17, 185-192.	4.9	18
121	Harnessing the Complexity of Data in Precision Oncology. , 2021, , 347-351.		0
122	How to Achieve a Good Phage Therapy Clinical Trial?. , 2019, , 147-168.		4
123	The Platform Vector Gene Therapies Project: Increasing the Efficiency of Adeno-Associated Virus Gene Therapy Clinical Trial Startup. Human Gene Therapy, 2020, 31, 1034-1042.	1.4	19
124	Phenotyping to Facilitate Accrual for a Cardiovascular Intervention. Journal of Clinical Medicine Research, 2019, 11, 458-463.	0.6	5
125	The Range and Scientific Value of Randomized Trials. Deutsches Ärztblatt International, 2017, 114, 635-640.	0.6	17
126	Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies. Ecanermedscience, 2019, 13, 936.	0.6	3
127	TRIUMPH Trial: One Small Step Could Become One Giant Leap for Precision Oncology in Head and Neck Cancer. Cancer Research and Treatment, 2019, 51, 413-414.	1.3	7
129	Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers. Statistics in Medicine, 2022, 41, 298-309.	0.8	5
130	Improving Clinical Trial Design in Gastrointestinal Oncology. , 2019, , 493-507.		0
131	Cancer Clinical Trials Based on Master Protocol. Japanese Journal of Biometrics, 2019, 39, 85-101.	0.0	1

#	ARTICLE	IF	CITATIONS
132	Understanding Clinical Trials in Malignant Mesothelioma. , 2019, , 187-202.		0
133	Integrated traditional Chinese and Western medicine in hepatocellular carcinoma treatment. World Chinese Journal of Digestology, 2019, 27, 459-466.	0.0	1
134	Diffuse large B-cell lymphoma: the stuff of cell-of-origin and microenvironment. Oncotarget, 2019, 10, 3991-3993.	0.8	0
135	Precision Trials Informatics. Computers in Health Care, 2020, , 215-222.	0.2	0
136	Current Status and Future Prospects of Biomarker Strategy for Drug Development. Japanese Journal of Clinical Pharmacology and Therapeutics, 2020, 51, 151-160.	0.1	0
137	Conducting economic evaluation based on basket clinical trial in the area of precision medicine. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 169-171.	0.7	2
138	Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. BMC Cancer, 2021, 21, 1180.	1.1	9
139	Inferential Frameworks for Clinical Trials. , 2021, , 1-30.		0
140	Master protocol trial design for technical feasibility of MR-guided radiotherapy. Radiotherapy and Oncology, 2022, 166, 33-36.	0.3	1
141	Of some innovations in clinical trial design in hematology and oncology. Therapie, 2021, , .	0.6	0
142	Master Protocols for Precision Medicine in Oncology: Overcoming Methodology of Randomized Clinical Trials. Life, 2021, 11, 1253.	1.1	6
143	Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan. Pharmaceutical Statistics, 2022, , .	0.7	2
144	Bayesian basket trial design with false-discovery rate control. Clinical Trials, 2022, , 174077452110736.	0.7	4
145	Novel clinical trial design and analytic methods to tackle challenges in therapeutic development in rare diseases. Annals of Translational Medicine, 2021, .	0.7	3
147	Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren. Springer Reference Medizin, 2021, , 1-57.	0.0	0
148	Cancer Precision Drug Discovery Using Big Data and Artificial Intelligence Technologies. Advances in Computational Intelligence and Robotics Book Series, 2022, , 109-136.	0.4	0
149	Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial. BMC Medical Research Methodology, 2022, 22, 49.	1.4	3
150	Future of Clinical Trial Methodology. Anesthesia and Analgesia, 2022, 134, 668-673.	1.1	4

#	ARTICLE	IF	CITATIONS
151	Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases. <i>Science Advances</i> , 2022, 8, eabl4370.	4.7	13
152	Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. <i>Health Technology Assessment</i> , 2021, 25, 1-228.	1.3	7
153	Starring Role of Biomarkers and Anticancer Agents as a Major Driver in Precision Medicine of Cancer Therapy. <i>Current Molecular Medicine</i> , 2023, 23, 111-126.	0.6	1
155	Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. <i>Trials</i> , 2022, 23, 372.	0.7	4
156	Adaptive Designs: Benefits and Cautions for Neurosurgery Trials. <i>World Neurosurgery</i> , 2022, 161, 316-322.	0.7	4
157	Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders. <i>Frontiers in Pharmacology</i> , 2022, 13, 775217.	1.6	1
158	Current usage and challenges of master protocols based on survey results by ASA BIOP oncology methodology working group master protocol sub-team. <i>Annals of Translational Medicine</i> , 2022, 10, 1036-1036.	0.7	1
159	Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	4
160	Bayesian local exchangeability design for phase II basket trials. <i>Statistics in Medicine</i> , 0, , .	0.8	2
161	Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges. <i>Clinical Trials</i> , 2022, 19, 561-572.	0.7	2
162	Inferential Frameworks for Clinical Trials. , 2022, , 973-1002.		0
163	Bayesian sample size determination in basket trials borrowing information between subsets. <i>Biostatistics</i> , 0, , .	0.9	2
164	A scoping review on patient heterogeneity in economic evaluations of precision medicine based on basket trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 0, , 1-10.	0.7	0
165	Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets. <i>PLoS ONE</i> , 2022, 17, e0272367.	1.1	3
166	An adaptive biomarker basket design in phase II oncology trials. <i>Pharmaceutical Statistics</i> , 2023, 22, 128-142.	0.7	2
167	Challenges, opportunities, and innovative statistical designs for precision oncology trials. <i>Annals of Translational Medicine</i> , 2022, 10, 1038-1038.	0.7	2
168	How Genome-Wide Analysis Contributes to Personalized Treatment in Cancer, Including Gynecologic Cancer?. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 115-132.	0.0	0
169	Design and analysis of umbrella trials: Where do we stand?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2

#	ARTICLE	IF	CITATIONS
170	Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers. <i>JCI Insight</i> , 2022, 7, .	2.3	16
171	A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target. <i>European Journal of Cancer</i> , 2023, 178, 227-233.	1.3	3
172	Prospects and Challenges in the Treatment of Solid Tumors. <i>Environmental Chemistry for A Sustainable World</i> , 2022, , 489-508.	0.3	1
173	Platform trials for anaesthesia and perioperative medicine: a narrative review. <i>British Journal of Anaesthesia</i> , 2023, 130, 677-686.	1.5	3
174	Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. <i>Clinical Cancer Research</i> , 2023, 29, 1047-1055.	3.2	5
175	Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial. <i>Statistical Methods in Medical Research</i> , 2023, 32, 963-977.	0.7	1
176	Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2023, 193, 30-43.	0.7	4
177	Practical basket design for binary outcomes with control of family-wise error rate. <i>BMC Medical Research Methodology</i> , 2023, 23, .	1.4	0
178	Basket Trials and Umbrella Trials. , 2023, , 87-100.		0
179	Clinical Trials for Personalized Medicine: Design and Data Analysis. <i>Japanese Journal of Biometrics</i> , 2022, 43, 97-119.	0.0	0
181	Can Rare Cancer Drugs Expect Sales in Japan?: A Prescription Pattern Analysis of Drugs for Chronic Myelogenous Leukemia and Neuroendocrine Tumor. , 0, , 1-9.		0
182	Principes du ciblage th�rapeutique. , 2023, , 155-165.		0
184	Zukunftspotenziale der Labormedizin. , 2023, , 181-231.		0
196	Cancer Precision Drug Discovery Using Big Data and Artificial Intelligence Technologies. , 2023, , 400-427.		0